GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Ending Cash Position

Allakos (STU:37Z) Ending Cash Position : €40.97 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Allakos Ending Cash Position?

Allakos's Ending Cash Position for the quarter that ended in Mar. 2024 was €40.97 Mil.

Allakos's quarterly Ending Cash Position declined from Sep. 2023 (€67.46 Mil) to Dec. 2023 (€62.28 Mil) and declined from Dec. 2023 (€62.28 Mil) to Mar. 2024 (€40.97 Mil).

Allakos's annual Ending Cash Position declined from Dec. 2021 (€137.26 Mil) to Dec. 2022 (€83.72 Mil) and declined from Dec. 2022 (€83.72 Mil) to Dec. 2023 (€62.28 Mil).

Allakos Ending Cash Position Historical Data

The historical data trend for Allakos's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Ending Cash Position Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 36.58 172.17 137.26 83.72 62.28

Allakos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.03 63.55 67.46 62.28 40.97

Allakos Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Allakos's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=81.328+-19.053
=62.28

Allakos's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=62.479+-21.51
=40.97

Allakos Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Allakos's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos (STU:37Z) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Ending Cash Position
Comparable Companies
AKBA STOK APLT VSTM ZVRA STRO GLUE IKNA OBIO QSI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ALLK:USA
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Website
https://www.allakos.com
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (STU:37Z) Headlines

No Headlines